Join our daily newsletter At The Bell to receive exclusive market insights
- Optiscan Imaging (OIL) has appointed Robert Cooke as Non-Executive Chair of the company
- Robert Cooke’s appointment comes with $100,000 in annual fixed remuneration, plus two million unlisted options exercisable at a 10 per cent premium to the closing share price
- Following the new appointment, Darren Lurie will become the Managing Director of the company
- Darren’s current executive services agreement has been amended to include a fixed remuneration of $375,000 per annum, with an optional long-term incentive plan
- OptiScan is up 24 per cent, trading at 31 cents
Optiscan Imaging (OIL) has appointed Robert Cooke as Non-Executive Chair Chair of the company.
Robert Cooke’s appointment comes with $100,000 in annual fixed remuneration, plus two million unlisted options exercisable at a 10 per cent premium to the closing share price.
Robert brings his background in the private health care sector to the role, with more than 40 years’ experience in the health industry. He previously held the role of Managing Director and CEO of Healthscope, one of Australia’s leading hospital, medical centre and pathology operators and has also held non-executive director positions at Icon Group and Evercare Group.
Following the new appointment, Darren Lurie will become the Managing Director of the company.
“It is a fantastic opportunity for OptiScan to secure someone of Mr Cooke’s capabilities and track record to lead our board,” said Darren Lurie.
“His knowledge of international corporate activity and multiple aspects of the health care sector, including private health, pathology, pharmacy, radiology and IVF, will provide enormous benefit to the company”.
Darren’s current executive services agreement has been amended to include a fixed remuneration of $375,000 per annum, with an optional long-term incentive plan.
Robert Cooke’s appointment comes with a $100,000 yearly fixed remuneration, plus two million unlisted options exercisable at a 10 per cent premium to the closing share price.
“I am excited to join the board of the company as the Chair and to support the current team at OptiScan in the next stage of its dynamic growth plans,” said Robert Cooke.
“With its collaborations with world-class research and medical institutions, the company is well-placed to embark on the global commercialisation of its world-leading technology in Oral cancer screening and surgery as well as pursuing additional clinical applications.”
“The ability of OptiScan’s unique confocal technology to provide instantaneous, live imaging at a cellular level has the opportunity to revolutionise cancer screening and surgical practices with the resulting benefits for patient care.”
OptiScan is up 24 per cent, trading at 31 cents at 12:30 pm AEST.
